Interferon alfacon-1: A novel interferon for the treatment of chronic hepatitis C

BioDrugs

Volumn 12, Issue 5, 1999, Pages 343-357

  Alberti, Alfredo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; CONSENSUS INTERFERON; RIBAVIRIN;

ALOPECIA; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEVER; HEPATITIS C; HEPATITIS VIRUS; HISTOLOGY; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LIVER CIRRHOSIS; LIVER FIBROSIS; MYALGIA; PRIORITY JOURNAL; RACE DIFFERENCE; RELAPSE; REVIEW; VIRUS CONCENTRATION;

EID: 0032730286     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199912050-00003     Document Type: Review

References (27)

1. Cantell K, Valle M. The ability of Sendai virus to overcome cellular resistance to vesicular stomatitis virus. II. The possible role of interferon. Ann Med Exp Biol Fenn 1965; 43 (2): 61-4
2. DeMaeyer J, DeMaeyer-Guignard J. Interferons and other regulatory cytokines. New York: John Wiley & Sons, 1998
3. Zoon KC, Zur Nedden DL, Enterline JC, et al. Chemical and biological characterization of natural human lymphoblastoid interferon alphas. In: Cantell K, Schellekens H, editors. The biology of the interferon system. Amsterdam: Martinus Nijhoff Publishers, 1986
4. Alton K, Stabinsky Y, Richard R, et al. Production, characterization, and biological effects of recombinant DNA derived human IFN-α and IFN-β analogs. In: De Maeyer E, Schellekens H, editors. The biology of the interferon system. Amsterdam: Elsevier Science Publishers, 1983; 119-28
5. Ozes ON, Reiter Z, Klein S, et al. A comparison of interferon-con, with natural recombinant interferons-α: antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res 1992; 12: 55-9
6. Blatt LM, Davis JM, Klein S, et al. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, interferon alfacon-1. J Interferon Cytokine Res 1996; 16: 489-99
7. Tong MJ, Blatt LM, Resser KJ, et al. Treatment of chronic hepatitis C virus infection with recombinant consensus interferon. J Interferon Cytokine Res 1998 Feb; 18 (2): 81-6
8. Tong MJ, Reddy KR, Lee WM, et al., Consensus Interferon Study Group. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Hepatology 1997; 26: 747-54
9. Poynard T, Leroy V, Cohard M, et al. Metaanalysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-89
10. Tong MJ, Blatt LM, McHutchinson JG, et al. Prediction of response during interferon alpha 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26: 1640-5
11. Pockros PJ, Bain VG, Hunter EB, et al. A comparison of RT- PCR and hDNA assays for hepatitis C virus in patients receiving interferon treatment. J Viral Hepatitis 1999; 6: 145-50
12. Stuyver L, Rossau R, Wyseur A, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74: 1093-102
13. Pockros PJ, Tong M, Lee WM, et al., Consensus Interferon Study Group. Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. J Viral Hepatitis 1998 Jul; 5 (4): 271-6
14. Lee WM, Reddy KR, Tong MJ, et al., Consensus Interferon Study Group. Early hepatitis C virus-RNA responses predict Interferon treatment outcomes in chronic hepatitis C. Hepatology 1998 Nov; 28 (5): 1411-5
15. Jensen DM, Krawitt EL, Keeffe EB, et al., Consensus Interferon Study Group. Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Am J Gastroenterol. In press
16. Reddy KR, Hoofnagle JH, Tong MJ, et al., Consensus Interferon Study Group. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999; 30 (3): 787-93
17. Jensen D, Shafritz D, Craig JR, et al. Nonresponders to CIFN show clinically relevant improvements in liver histology [abstact]. Gastroenterology 1997; 1 (12): 1294A
18. Schalm SW, Fattovich G, Brouwer JT. Therapy of hepatitis C: patients with cirrhosis. Hepatology 1997; 26 Suppl. 1: 128- 32S
19. Everson GT, Jensen DM, Craig JR, et al., Consensus Interferon Study Group. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics or nonfibrotics. Hepatology 1999; 30: 271-6
20. Heathcote EJ, Keeffe EB, Lee SS, et al. Retreatment of chronic hepatitis C with consensus interferon. Hepatology 1998; 27: 1136-43
21. [20]
22. Davis GL, Esteban-Mur R, Rustgi V, et al., Internatioiuil Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998 Nov; 339 (21): 1493-9
23. Alberti A. Retreatment with interferon. In: Proceedings of the NIH Consensus Development Conference on management of hepatitis C. Hepatology 1997; 26 (3) Suppl. 1: 137S-42S
24. Puoti M, Castelnuovo F, Rossi S, et al. Retreatment of patients with chronic hepatitis C (CHC) without primary response to interferon-alpha is uneffective. IX Triennial International Symposium on Viral Hepatitis and Liver Disease, April 1996, Rome, Italy. Abstract no: D 195
25. Giudici Cipriani A, Ponassi I, Varagona G, et al. Retreatment of patients with chronic hepatitis C non-responders to a first interferon course: analysis of a large patient cohort. Hepatology 1996; 24: 273A
26. Chemello L, Cavalletto L, Dunada C, et al. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. Gastroenterology 1997; 113 (5): 1654-9
27. Chow WC, Boyer N, Pouteau M, et al. Re-treatment with interferon alfa of patients with chronic hepatitis C. Hepatology 1998; 27 (4): 1144-8